Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-412-8400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.04 million
Profitability
Miscellaneous
Employees77
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable
Tocagen (NASDAQ:TOCA) Frequently Asked Questions
What is Tocagen's stock symbol?
Tocagen trades on the NASDAQ under the ticker symbol "TOCA."
How were Tocagen's earnings last quarter?
Tocagen Inc (NASDAQ:TOCA) released its earnings results on Tuesday, November, 12th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by $0.10. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. Tocagen had a negative return on equity of 182.15% and a negative net margin of 201,488.91%. View Tocagen's Earnings History.
When is Tocagen's next earnings date?
What price target have analysts set for TOCA?
9 Wall Street analysts have issued 12-month price targets for Tocagen's shares. Their forecasts range from $1.00 to $28.00. On average, they expect Tocagen's share price to reach $11.42 in the next year. This suggests a possible upside of 1,741.1% from the stock's current price. View Analyst Price Targets for Tocagen.
What is the consensus analysts' recommendation for Tocagen?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 9 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tocagen.
What are Wall Street analysts saying about Tocagen stock?
Here are some recent quotes from research analysts about Tocagen stock:
- 1. According to Zacks Investment Research, "Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company's lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. " (11/21/2019)
- 2. HC Wainwright analysts commented, "We lower our rating of TOCA to and considering the limited visibility of company’s pipeline development strategy going forward, we are not comfortable to determine a specific price target. (1) clinical; (2) commercial; (3) partnership; (4) financial; and (5) intellectual property. Tocagen, Inc. September 12, 2019 H.C. WAINWRIGHT & CO." (9/12/2019)
Has Tocagen been receiving favorable news coverage?
Media headlines about TOCA stock have trended positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tocagen earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Tocagen.
Who are some of Tocagen's key competitors?
Some companies that are related to Tocagen include Medicure (MCUJF), VERONA PHARMA P/S (VRNA), Infinity Pharmaceuticals (INFI), Pharmaxis (PXSLY), Proteostasis Therapeutics (PTI), Adamis Pharmaceuticals (ADMP), Novan (NOVN), Merrimack Pharmaceuticals (MACK), Spring Bank Pharmaceuticals (SBPH), AgeX Therapeutics (AGE), IntelGenx Technologies (IGXT), Cyclerion Therapeutics (CYCN), SUMMIT THERAPEU/S (SMMT), Kezar Life Sciences (KZR) and Alpine Immune Sciences (ALPN).
What other stocks do shareholders of Tocagen own?
Who are Tocagen's key executives?
Tocagen's management team includes the folowing people:
- Mr. Martin J. Duvall, CEO & Director (Age 57)
- Mr. Thomas E. Darcy, Co-Founder & Director (Age 68)
- Dr. Douglas J. Jolly, Co-Founder and Exec. VP of Research & Pharmaceutical Devel. (Age 71)
- Mr. Mark G. Foletta C.P.A., CPA, Exec. VP & CFO (Age 58)
- Dr. Harry E. Gruber, Founder, Adviser & Director (Age 66)
When did Tocagen IPO?
(TOCA) raised $80 million in an IPO on Thursday, April 13th 2017. The company issued 7,300,000 shares at a price of $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.
How do I buy shares of Tocagen?
Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Tocagen's stock price today?
One share of TOCA stock can currently be purchased for approximately $0.62.
How big of a company is Tocagen?
Tocagen has a market capitalization of $14.82 million and generates $18.04 million in revenue each year. The company earns $-48,960,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Tocagen employs 77 workers across the globe.View Additional Information About Tocagen.
What is Tocagen's official website?
How can I contact Tocagen?
Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]
MarketBeat Community Rating for Tocagen (NASDAQ TOCA)
MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe TOCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TOCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
